A5038204351- Renal Transplantation Outcomes and Treatments
- Dialysis and Renal Disease Management
- Organ Donation and Transplantation
- Health Systems, Economic Evaluations, Quality of Life
- RNA Research and Splicing
- RNA Interference and Gene Delivery
- Economic and Financial Impacts of Cancer
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Immune Cell Function and Interaction
- Meta-analysis and systematic reviews
- HIV Research and Treatment
- Medication Adherence and Compliance
- Cancer survivorship and care
- Risk Perception and Management
- Advanced biosensing and bioanalysis techniques
- Complement system in diseases
- Bladder and Urothelial Cancer Treatments
- Pregnancy and Medication Impact
- Renal cell carcinoma treatment
- Disaster Management and Resilience
- Public Relations and Crisis Communication
- Urinary and Genital Oncology Studies
Clinical Solutions
2022-2024
Health Outcomes Solutions (United States)
2024
San Diego State University
2020
Terasaki Foundation
2019
University of California, San Diego
2013
Locally advanced/metastatic urothelial cancer (la/mUC) affects patients' quality of life (QOL) and functioning. We describe the impact first-line (1L) enfortumab vedotin (EV) alone or with pembrolizumab (P) on QOL/functioning/symptoms in patients la/mUC who were cisplatin-ineligible from EV-103 Cohort K.
Abstract Circulating cell-free mRNA (cf-mRNA) holds great promise as a non-invasive diagnostic biomarker. However, cf-mRNA composition and its potential clinical applications remain largely unexplored. Here we show, using Next Generation Sequencing-based profiling, that is enriched in transcripts derived from the bone marrow compared to circulating cells. Further, longitudinal studies involving ablation followed by hematopoietic stem cell transplantation multiple myeloma acute myeloid...
Understanding the correlation between transplant symptoms, health-related quality of life (HRQoL), and graft outcomes is needed to support patient-focused drug development posttransplant management. A post-hoc analysis patient-reported from Phase III belatacept trials was conducted in order investigate interrelationship trajectories HRQoL, symptom experience, allograft outcomes. HRQoL experience were evaluated using Short-Form 36 Survey (SF-36) Modified Transplant Symptom Occurrence Distress...
Background and objectives Many individuals with kidney disease, particularly those belonging to racial ethnic minority groups whose primary language is not English, lack knowledge related disease symptoms, physiologic functions of the kidney, benefits risks transplantation. Valid instruments assess patients’ CKD transplantation are needed. Design, setting, participants, & measurements Using a sample 977 patients stages 3–5 in Kaiser Permanente health system, we developed Knowledge...
Objectives. To examine how and what information is communicated via social media during an infectious disease outbreak. Methods. In the context of 2016 through 2018 hepatitis A outbreak in San Diego County, California, we used a grounded theory–based thematic analysis that employed qualitative quantitative approaches to uncover themes sample public tweets (n = 744) from Twitter, primary platform by key stakeholders communicate Results. Tweets contained both general A–specific related...
ABSTRACT Inflammation during HIV infection is associated with worse disease outcomes and progression. Many mechanisms have been indicted, including itself, coinfections, gut microbial translocation. Concerning translocation, we hypothesized that adaptive immune responses to a specific bacterial species known be present in gut-associated lymphoid tissue are higher among HIV-infected individuals than HIV-uninfected controls T cell activation lower CD4 counts. By characterizing the IgG response...
384 Background: Cabozantinib plus nivolumab (CN) is a 1L therapy for aRCC. In the CM9ER trial CN had superior efficacy to sunitinib (SUN) and showed HRQoL benefit. We investigated relationship between clinical outcomes, treatment early deterioration in dimensions population. Methods: Using intention-to-treat (ITT) population (median follow-up 32.9 months) we: (a) explored time-to-event outcomes vs SUN (b) identified determinants of benefit by performing ordinal regression using 19-item...
Abstract Circulating cell free mRNA (cf-mRNA) holds great promise as a non-invasive diagnostic biomarker. However, the biological origin of cf-mRNA is still not well understood, limiting clinical applications this technology. Here, we use bone marrow (BM) and pharmacologic manipulation its resident cells window to study cf-mRNA. Using NGS-based profiling, show that enriched in transcripts derived from BM compared circulating cells. Further, ablation experiments followed by hematopoietic stem...